Amphastar Pharmaceuticals (AMPH) PT Lowered to $20 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2017
May 8, 2017 4:05 PM EDTRANCHO CUCAMONGA, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (Amphastar or the Company) today reported results for the three months ended March 31, 2017.
First Quarter Highlights
Net revenues of $56.7 million for the first quarterGAAP net income of $0.9 million, or $0.02 per diluted share, for the first quarterAdjusted non-GAAP net income of $4.5 million, or $0.09 per diluted share, for the first quarterDr. Jack Zhang, Amphastars CEO, commented:Â We continue to execute on our... More
